Pan Wang
Sun Yat-sen University
17 Papers
Pan Wang is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Lin Quan Tang,Dong Ping Chen,Ling Guo,Hao Yuan Mo,Ying Huang,Shan Shan Guo,Bin Qi,Qing Nan Tang,Pan Wang,Xiao Yun Li,Jibin Li,Qing Liu,Yuanhong Gao,Fang Yun Xie,Li Ting Liu,Yang Li,Sai Lan Liu,Hao Jun Xie,Yu Jing Liang,Xue Song Sun,Jin Jie Yan,Yi Shan Wu,Dong Hua Luo,Pei Yu Huang,Yan Qun Xiang,Rui Sun,Ming-Yuan Chen,Xing Lv,Lin Wang,Wei Xiong Xia,Chong Zhao,Ka Jia Cao,Chao-Nan Qian,Xiang Guo,Ming-Huang Hong,Zhi Qiang Nie,Qiu Yan Chen,Hai-Qiang Mai +37 more
TL;DR: This trial assessed whether a nedaplatin-based concurrent chemoradiotherapy regimen was non-inferior to a cisplatin -based regimen in patients with locoregional, stage II-IVB nasopharyngeal carcinoma in China.
133
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Han Li,Zhen-Feng Wu,Jiali Chen,Ke Su,Lu Guo,Ke Xu,T. Gu,Yi Jiang,Pan Wang,Hao Zeng,Hao Chi,Kun He,Junwei Han +12 more
TL;DR: In this article , a meta-analysis aimed to compare efficacy of three combination strategies in treatment of advanced unresectable HCC with a view of guiding future selection of the best combination therapy for sorafenib and local therapy.
A phase 2 Randomised Controlled Trial of Adjuvant Tumor-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients
Yu-Jing Liang,Quan Chen,Jing-Xiao Xu,Xiu-Feng Liu,Jian Chuan Xia,Li-Ting Liu,Shan-Shan Guo,Bin Song,Pan Wang,Jibin Li,Qiang Liu,Hao Yuan Mo,Ling Guo,Rui Sun,Dong Hua Luo,Jia He,Yina Liu,Caiping Nie,Lin-Quan Tang,Jing Li,Hai Qiang Mai +20 more
TL;DR: In this article , the safety and objective clinical responses were observed in the phase I study using adjuvant autologous tumor-infiltrating lymphocytes (TILs) following concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma patients.
7
Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Yu-Jing Liang,Dong-Xiang Wen,Mei-Juan Luo,Lin-Quan Tang,Shan-Shan Guo,Pan Wang,Qiu-Yan Chen,Li-Ting Liu,Hai-Qiang Mai +8 more
TL;DR: In this article, the authors compared the prognosis and adverse effects of induction or adjuvant chemotherapy (IC or AC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in paediatric nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era.
4
Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
Yu-Jing Liang,Li-Ting Liu,Yang Li,Pan Wang,Mei-Juan Luo,Dongxiang Wen,Quan Chen,Hai Qiang Mai +7 more
TL;DR: This cohort study investigates the association of advances in imaging diagnosis, radiotherapy techniques, and treatment methods with survival among pediatric patients with nasopharyngeal carcinoma in China from 1989 to 2020.